Category - Developments

Nabriva Therapeutics (NASDAQ:NBRV) reported positive top-line results from its LEAP 2 clinical trial, the second of two global, Phase 3 clinical trials of its antibiotic, lefamulin. LEAP 2 evaluated the safety and...

Closely-held Tear Film Innovations completed an $8.5-million Series B preferred stock round led by Visionary Ventures Fund and Bluestem Capital. “This successful funding round completes the capitalization for our growth...

Profound Medical (TSXV:PRN; OTCQX:PRFMF) presented positive initial data from its TACT pivotal study with its TULSA-PRO ablation device at the American Urological Association (AUA) annual meeting in San Francisco. The...

Closely-held CellAegis announced completion of patient enrollment in a large investigator sponsored trial to further assess the efficacy of remote ischemic conditioning (RIC) using its autoRIC device to deliver the RIC...

Canopy Growth (TSX:WEED) has agreed to acquire the shares it doesn’t already own in Canopy Health Innovations (CHI) and CHI’s subsidiary, Canopy Animal Health, bringing its affiliated research arm fully into the...

Zymeworks (NYSE, TSX:ZYME) and Daiichi Sankyo entered into a new license agreement, building on their 2016 cross-licensing and collaboration agreement. “With a successful track record and our first bispecific antibody...

3D Signa­­­­­­tures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) recently received a patent from the Canadian Intellectual Property office, which protects the company’s IP in the area of cognitive diseases in general and...

The Chinese Food and Drug Administration (CFDA) has approved Profound Medical’s (TSXV:PRN; OTCQX:PRFMF) Sonalleve for the non-invasive treatment of uterine fibroids. Sonalleve is a therapeutic platform that combines...

NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has joined forces with Vertical Companies, the largest fully integrated company in the legal medical cannabis industry, to launch NanoSphere’s Evolve product line in...

Achaogen (NASDAQ:AKAO) received a mixed review from an FDA advisory committee on its antibiotic, plazomicin, with a vote in favor of approval for complicated urinary tract infections but against its use in bloodstream...